Ruben Mesa
Is the President and Executive Director of · Carolinas Medical Center
Credentials: · · · · · · ·
History
PresentComprehensive Cancer Center · Wake Forest University Baptist Medical Center
- Present
Atrium Health Wake Forest Baptist Comprehensive Cancer Center · Wake Forest University Baptist Medical Center
- 1999–2002
Mayo Medical Center
- 1995–1998
Mayo Medical Center
1991–1995
Research
Cancer Cell · 2005 · 2,411 citations
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
New England Journal of Medicine · 2012 · 1,753 citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
The Lancet · 2020 · 1,345 citations
110 papers
- SV
98 papers
56 papers
41 papers · 29 as a resident
39 papers
35 papers
34 papers · 6 as a fellow
33 papers
Grants
- 2022–2027
National Cancer Institute · R01
PI · $2.8M · University of Texas Hlth Science Center
- 1997–2027
National Cancer Institute · P30
Contact PI · $12.1M · Wake Forest University Health Sciences
- 1997–2026
Mays Cancer Center at UT San Antonio Health Science Center
National Cancer Institute · P30
Contact PI · $13.4M · University of Texas Hlth Science Center
- 2002–2007
Apoptosis in Myelofibrosis with Myeloid Metaplasia
National Cancer Institute · K23
Contact PI · $618.7K · Mayo Clinic Rochester
Clinical trials
- 2022–2023
Calm for Cancer Patients Receiving Chemotherapy
Principal investigator · Withdrawn
The University of Texas Health Science Center at San Antonio
- 2020–2022
Principal investigator · Completed · Phase 3
Sierra Oncology LLC - a GSK company
- 2013–2017
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
Principal investigator · Completed · Phase 2
Mayo Clinic
- 2008–2012
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
Principal investigator · Completed · Phase 1, Phase 2
S*BIO